The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type...

Our SIOPEL-6 study showed that sodium thiosulfate (Pedmarqsi) almost halves the percentage of children and teenagers who lose hearing as...

“Patient response to revumenib has been good in other clinical trials,” explains Cuglievan. “But it’s also been short-lived when used...

There’s new evidence that Larotrectinib (Vitrakvi), by Loxo Oncology and Bayer, is highly effective in children with newly diagnosed...

The survival rate for children with a rare but deadly cancer could one day be improved by adding an existing drug—which is currently used...

Giselle Saulnier Sholler has spent 20 years working treatments for neuroblastoma, a particularly aggressive form of early childhood...

Larotrectinib led to rapid/durable responses and high disease control rates in children with TRK fusion-position central nervous system...

The FDA granted a rare pediatric disease designation to elraglusib (9-ING-41), a novel GSK-3β inhibitor, as a potential therapeutic...

Research at St. Jude recently showed that the drug capmatinib is effective at crossing the blood-brain-barrier, synergizing with...

The Food and Drug Administration (FDA) expanded the approval of Jylamvo (methotrexate) to include children with acute lymphoblastic...